TMCnet News
Tetraphase Pharmaceuticals to Present Data at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)WATERTOWN, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced seven data presentations at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 22-25 in Vienna, Austria. Presentations will include information about the company’s lead drug candidate, eravacycline, as well as data from its TP-6076 program. “The data we are presenting at ECCMID this year continue to demonstrate the potent activity of eravacycline against a wide range of bacteria, including multidrug-resistant pathogens that cause some of the most serious and life-threatening infections,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase Pharmaceuticals. “Eravacycline data show potent activity against many of the organisms identified by the World Health Organization and the U.S. Centers for Disease Control to pose urgent or serious threats to human health, specifically Gram-negative bacteria Acinetobacter baumannii and Enterobacteriaceae, including carbapenem-resistant or extended beta-lactamase producing phenotypes, as well as Gram-positive bacteria Staphylococcus aureus and enterococci, including methicillin- or vancomycin-resistant phenotypes.” Mr. Macdonald continued, “We are also very excited about the emerging profile of our earlier stage compound, TP-6076. Data presentations at ECCMID highlight its potency against multidrug-resistant Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae, demonstrated in clinical isolates that were pan-resistant to multiple antibiotic classes.” The details for the data presentations at ECCMID are as follows: Eravacycline presentations: Poster Title: In vitro activity of eravacycline and comparators against Staphylococcus aureus and enterococci, including methicillin-resistant and vancomycin-resistant subgroups, collected from European hospitals in 2015 Poster Title: In vitro activity of eravacycline and comparators against Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae, including carbapenem-resistant and ESBL phenotype subgroups, collected from European hospitals in 2015 Poster number: #P1260 Session info: New data on new tetracyclines; Paper poster session Poster title: Comparative in vitro activity of eravacycline, a novel fluorocycline, against mcr-1-positive Escherichia coli & Klebsiella pneumoniae Poster title: Eravacycline, a novel fluorocycline, has antibacterial activity against carbapenem-resistant Enterobacteriaceae (CRE) & Acinetobacter spp. (CRA) Poster title: Antibacterial activity of eravacycline, a novel fluorocycline, compared to established antimicrobials, against contemporary clinical isolates from Tanta, Egypt. TP-6076 presentations: Poster title: In-vitro activity of the novel fluorocycline TP-6076 against carbapenem non-susceptible Acinetobacter baumannii Poster title: TP-6076 is active against Carbapenem- and Polymyxin-resistant Enterobacteriaceae and Acinetobacter baumannii isolates in the FDA-CDC Antimicrobial Resistance Isolate Bank Panels. Full abstracts can be found on the ECCMID website at http://www.eccmid.org/. About Tetraphase Pharmaceuticals, Inc. Forward-Looking Statements Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Argot Partners Maeve Conneighton 206-899-4940 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected] |